ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Detection of EGFR mutations in plasma circulating tumour DNA as a selection criterion for first-line gefitinib treatment in patients with advanced lung adenocarcinoma (BENEFIT): a phase 2, single-arm, multicentre clinical trial.

Wang, Zhijie; Cheng, Ying; An, Tongtong; Gao, Hongjun; Wang, Kai; Zhou, Qing; Hu, Yanping; Song, Yong; Ding, Cuimin; Peng, Feng; Liang, Li; Hu, Yi; Huang, Cheng; Zhou, Caicun; Shi, Yuankai; Zhang, Li; Ye, Xin; Zhang, Meizhuo; Chuai, Shaokun; Zhu, Guanshan; Hu, Jin; Wu, Yi-Long*; Wang, Jie*四川大学; 中国医学科学院; 福建省肿瘤医院
Lancet Respir Med2018-9DOI: 10.1016/S2213-2600(18)30264-9
6阅读
引用收藏
分享

摘要

BACKGROUND: Detection of EGFR mutations in tumour tissue is the gold-standard approach to ascertain if a patient will benefit from treatment with an EGFR tyrosine kinase inhibitor. However, if tissue is scant, another strategy is to use circulating tumour DNA (ctDNA), but this method needs validation in clinical trials. We did a prospective clinical trial to assess ctDNA-based EGFR mutation detection as a selection criterion for patients with lung adenocarcinoma receiving gefitinib as first-line treatment. METHODS: BENEFIT is a multicentre, single-arm, phase 2 clinical trial at 15 centres in China. Patients aged 18-75 years with stage IV metastatic lung adenocarcinoma and EGFR mutations detected in ctDNA were given oral gefitinib 250 mg once daily as first-line treatment. The primary endpoint was the proportion achieving an objective response. Secondary endpoints included median progression-free survival and safety. Next-generation sequencing (NGS) of a 168-gene panel was used for genetic analysis of baseline blood samples. The primary efficacy analysis was done by intention to treat in patients who had at least one post-baseline tumour assessment. The safety analysis was done in all patients who received at least one dose of study treatment. This trial is registered with ClinicalTrials.gov, number NCT02282267. FINDINGS: Between Dec 25, 2014, and Jan 16, 2016, 426 patients were screened for the trial, of whom 188 with EGFR mutations in ctDNA were enrolled and received gefitinib. 183 patients had one or more post-baseline tumour assessment and were included in the primary efficacy analysis. Median follow-up was 14·5 months (IQR 12·2-16·5). At the time of data cutoff (Jan 31, 2017), 152 patients had progressive disease or had died. The proportion achieving an objective response was 72·1% (95% CI 65·0-78·5). Median progression-free survival was 9·5 months (95% CI 9·07-11·04). Of 167 patients with available blood samples, 147 (88%) showed clearance of EGFR mutations in ctDNA at week 8, and median progression-free survival was longer for these patients than for the 20 patients whose EGFR mutations persisted at week 8 (11·0 months [95% CI 9·43-12·85] vs 2·1 months [1·81-3·65]; hazard ratio [HR] 0·14, 95% CI 0·08-0·23; p<0·0001). From baseline NGS data in 179 patients, we identified three subgroups of patients: those with EGFR mutations only (n=58), those with mutations in EGFR and tumour-suppressor genes (n=97), and those with mutations in EGFR and oncogenes (n=24). Corresponding median progression-free survival in these subgroups was 13·2 months (95% CI 11·5-15·0), 9·3 months (7·6-11·0), and 4·7 months (1·9-9·3), respectively (EGFR mutations only vs mutations in EGFR and tumour-suppressor genes, HR 1·78, 95% CI 1·23-2·58; p=0·002; EGFR mutations only vs mutations in EGFR and oncogenes, 2·66, 1·58-4·49; p=0·0003). The most common grade 3 or 4 adverse events were hepatic function abnormalities (n=24). Serious adverse events were reported in 17 (9%) patients. No unexpected safety events for gefitinib were recorded. INTERPRETATION: Detection of EGFR mutations in ctDNA is an effective method to identify patients who might benefit from first-line gefitinib treatment. Further analyses of dynamic alterations of EGFR mutations and accompanying gene aberrances could predict resistance to gefitinib. FUNDING: Guangdong Association of Clinical Trials, AstraZeneca, National Natural Sciences Foundation Key Programme, and National Key Research and Development Programme of China.

相关
加载中…
  • EGFR mutation detection in circulating cell-free DNA of lung adenocarcinoma patients: analysis of LUX-Lung 3 and 6
    Wu Yi Long*; Sequist Lecia V; Hu Cheng Ping; Feng Jifeng; Lu Shun; Huang Yunchao; Li Wei; Hou Mei; Schuler Martin; Mok Tony; Yamamoto Nobuyuki; O'Byrne Kenneth; Hirsh Vera; Gibson Neil; Massey Dan; Kim Miyoung; Yang James Chih Hsin*British Journal of Cancer, 2017, 116(2): 175-185.
  • Analysis of circulating tumour DNA to identify patients with epidermal growth factor receptor–positive non-small cell lung cancer who might benefit from sequential tyrosine kinase inhibitor treatment
    Provencio Mariano; Serna-Blasco Roberto; Franco Fabio; Calvo Virgina; Royuela Ana; Auglytė Milda; Sánchez-Hernández Alfredo; de Julián Campayo María; García-Girón Carlos; Dómine Manuel; Blasco Ana; Sánchez José M.; Oramas Juana; Bosch-Barrera Joaquim; Sala María Á.; Sereno María; Ortega Ana L.; Chara Luis; Hernández Berta; Padilla Airam; Coves Juan; Blanco Remedios; Balsalobre José; Mielgo Xabier; Bueno Coralia; Jantus-Lewintre Eloisa; Molina-Vila Miguel Á.; Romero AtochaEuropean Journal of Cancer, 2021, 149.
  • Relative Abundance of EGFR Mutations Predicts Benefit From Gefitinib Treatment for Advanced Non-Small-Cell Lung Cancer
    Zhou Qing; Zhang Xu Chao; Chen Zhi Hong; Yin Xiao Lu; Yang Jin Ji; Xu Chong Rui; Yan Hong Hong; Chen Hua Jun; Su Jian; Zhong Wen Zhao; Yang Xue Ning; An She Juan; Wang Bin Chao; Huang Yi Sheng; Wang Zhen; Wu Yi Long*Journal of Clinical Oncology, 2011, 29(24): 3316-3321.被引 80
查看全部 →

发表信息

论文状态
公开发表
期刊
Lancet Respir Med
发表日期
2018-09
卷期
第 6 卷, 第 9 期
页码
681-690
DOI
10.1016/S2213-2600(18)30264-9
成果收录
PUBMED

作者

  • W

    Wang, Zhijie (第一作者)

    chinese academy of medical sciences

  • C

    Cheng, Ying

查看全部 23 位作者收起作者
  • A

    An, Tongtong

  • G

    Gao, Hongjun

  • W

    Wang, Kai

  • Z

    Zhou, Qing

  • H

    Hu, Yanping

  • S

    Song, Yong

  • D

    Ding, Cuimin

  • P

    Peng, Feng

    sichuan university

  • L

    Liang, Li

  • H

    Hu, Yi

  • H

    Huang, Cheng

    fujian provincial cancer hospital

  • Z

    Zhou, Caicun

  • S

    Shi, Yuankai

    chinese academy of medical sciences

  • Z

    Zhang, Li

  • Y

    Ye, Xin

  • Z

    Zhang, Meizhuo

  • C

    Chuai, Shaokun

  • Z

    Zhu, Guanshan

  • H

    Hu, Jin

  • W

    Wu, Yi-Long (通讯)

  • W

    Wang, Jie (通讯)

    chinese academy of medical sciences

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417